Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of British Columbia
$27,000.00
Exploring the role of A20 in improving stem cell-derived B-cell transplant survival and function through reducing NF-kappaB signalling and inflammation
EF 2025-26
Résumé
Type 1 diabetes (T1D) occurs when the body's immune system destroys insulin-producing B-cells in the pancreas, needed for blood sugar (glucose) regulation. This leads to life threatening complications, and leaves patients reliant on insulin injections that significantly affect quality of life and often lead to poor glucose control. B-cell transplants using human donors are a promising treatment, but the clinical applicability of this therapy is hindered by donor shortage as well as cell death following transplantation, caused by inflammation and activation of NF-?B signalling. Stem cells are cells capable of transforming into any cell type in the body, potentially providing unlimited numbers of cells for transplantation. B-cells derived from stem cells (SC-B-cells) are a scalable alternative to human donor B-cells and can be engineered to enhance survival and function. One important protein, A20, has been shown to be able to protect B-cells from dying in response to inflammation by inhibiting NF-?B signalling. We hypothesize that engineering SC-B-cells to produce A20 will protect them from inflammation and improve their survival after transplantation. To do this, stem cells will be engineered using gene editing methods to produce A20 and then differentiated into B-cells. These cells will be assessed for normal function and resistance to inflammatory stressors. Subsequently, they will be transplanted into mice to determine whether A20 production increases survival of SC-B-cells in the body. These findings could identify a novel strategy to improve SC-B-cell replacement therapies and provide a lasting treatment to those with T1D.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
572641
Name
Gao Raymond J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the role of A20 in improving stem cell-derived B-cell transplant survival and function through reducing NF-kappaB signalling and inflammation
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Beta Cell; Diabetes; Inflammation; Regenerative Medicine; Stem Cells; Transplantation
Abstract
Type 1 diabetes (T1D) occurs when the body's immune system destroys insulin-producing B-cells in the pancreas, needed for blood sugar (glucose) regulation. This leads to life threatening complications, and leaves patients reliant on insulin injections that significantly affect quality of life and often lead to poor glucose control. B-cell transplants using human donors are a promising treatment, but the clinical applicability of this therapy is hindered by donor shortage as well as cell death following transplantation, caused by inflammation and activation of NF-?B signalling. Stem cells are cells capable of transforming into any cell type in the body, potentially providing unlimited numbers of cells for transplantation. B-cells derived from stem cells (SC-B-cells) are a scalable alternative to human donor B-cells and can be engineered to enhance survival and function. One important protein, A20, has been shown to be able to protect B-cells from dying in response to inflammation by inhibiting NF-?B signalling. We hypothesize that engineering SC-B-cells to produce A20 will protect them from inflammation and improve their survival after transplantation. To do this, stem cells will be engineered using gene editing methods to produce A20 and then differentiated into B-cells. These cells will be assessed for normal function and resistance to inflammatory stressors. Subsequently, they will be transplanted into mice to determine whether A20 production increases survival of SC-B-cells in the body. These findings could identify a novel strategy to improve SC-B-cell replacement therapies and provide a lasting treatment to those with T1D.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gao, Raymond J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~